73 related articles for article (PubMed ID: 10022026)
1. Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model.
Guinan P; Shaw M; Mirochnik Y; Slobodskoy L; Ray V; Rubenstein M
Methods Find Exp Clin Pharmacol; 1998 Nov; 20(9):739-42. PubMed ID: 10022026
[TBL] [Abstract][Full Text] [Related]
2. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
Jackson JK; Gleave ME; Yago V; Beraldi E; Hunter WL; Burt HM
Cancer Res; 2000 Aug; 60(15):4146-51. PubMed ID: 10945622
[TBL] [Abstract][Full Text] [Related]
3. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
Sweeney P; Karashima T; Kim SJ; Kedar D; Mian B; Huang S; Baker C; Fan Z; Hicklin DJ; Pettaway CA; Dinney CP
Clin Cancer Res; 2002 Aug; 8(8):2714-24. PubMed ID: 12171905
[TBL] [Abstract][Full Text] [Related]
5. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
[TBL] [Abstract][Full Text] [Related]
6. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
El Hilali N; Rubio N; Blanco J
Clin Cancer Res; 2005 Feb; 11(3):1253-8. PubMed ID: 15709196
[TBL] [Abstract][Full Text] [Related]
7. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
[TBL] [Abstract][Full Text] [Related]
8. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
Chen CT; Gan Y; Au JL; Wientjes MG
Cancer Res; 1998 Jul; 58(13):2777-83. PubMed ID: 9661891
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
10. A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG
Cancer Res; 2003 Feb; 63(3):593-9. PubMed ID: 12566301
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice.
Zhang ZL; Liu ZS; Sun Q
Chin Med J (Engl); 2005 Oct; 118(20):1688-94. PubMed ID: 16313753
[TBL] [Abstract][Full Text] [Related]
12. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
13. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors.
Leung SY; Jackson J; Miyake H; Burt H; Gleave ME
Prostate; 2000 Jul; 44(2):156-63. PubMed ID: 10881025
[TBL] [Abstract][Full Text] [Related]
14. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
Lapidus RG; Dang W; Rosen DM; Gady AM; Zabelinka Y; O'Meally R; DeWeese TL; Denmeade SR
Prostate; 2004 Feb; 58(3):291-8. PubMed ID: 14743469
[TBL] [Abstract][Full Text] [Related]
16. Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.
Liu CM; Lo YC; Tai MH; Wu BN; Wu WJ; Chou YH; Chai CY; Huang CH; Chen IJ
Prostate; 2009 May; 69(6):610-23. PubMed ID: 19143029
[TBL] [Abstract][Full Text] [Related]
17. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer.
Rothermund CA; Kondrikov D; Lin MF; Vishwanatha JK
Prostate Cancer Prostatic Dis; 2002; 5(3):236-45. PubMed ID: 12496988
[TBL] [Abstract][Full Text] [Related]
20. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene.
Fraizer G; Leahy R; Priyadarshini S; Graham K; Delacerda J; Diaz M
Int J Oncol; 2004 Mar; 24(3):461-71. PubMed ID: 14767530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
